Recovery of functional memory T cells in lung transplant recipients following induction therapy with alemtuzumab

American Journal of Transplantation

Volumn 7, Issue 2, 2007, Pages 471-475

  Zeevi, A ^a   Husain, S ^a   Spichty, K J ^a   Raza, K ^a   Woodcock, J B ^b   Zaldonis, D ^a   Carruth, L M ^b   Kowalski, R J ^b   Britz, J A ^b   McCurry, K R ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b Cylex Incorporated   (United States)

Author keywords

CMV; Depletion; Memory; T cell; Transplantation

Indexed keywords

ALEMTUZUMAB; CONCANAVALIN A; MITOGENIC AGENT; PHYTOHEMAGGLUTININ; VALGANCICLOVIR;

ARTICLE; CELL ASSAY; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS; GRAFT RECIPIENT; HUMAN; IMMUNE FUNCTION TEST; LONGITUDINAL STUDY; LUNG GRAFT REJECTION; LUNG TRANSPLANTATION; LYMPHOCYTE DEPLETION; LYMPHOCYTE FUNCTION; MEMORY T LYMPHOCYTE; PRIORITY JOURNAL; PROPHYLAXIS;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; CONCANAVALIN A; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; HUMANS; IMMUNOLOGIC MEMORY; IMMUNOSUPPRESSION; LONGITUDINAL STUDIES; LUNG TRANSPLANTATION; LYMPHOCYTE DEPLETION; MITOGENS; PHYTOHEMAGGLUTININS; RISK FACTORS; T-LYMPHOCYTE SUBSETS;

EID: 33846240793     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2006.01641.x     Document Type: Article

References (25)

1. Calne R, Friend P, Moffatt S et al. Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients. Lancet 1998; 351: 1701-1702.
2. Starzl TE, Murase N, bu-Elmagd K et al. Tolerogenic immunosuppression for organ transplantation. Lancet 2003; 361: 1502-1510.
3. Kirk AD, Hale DA, Mannon RB et al. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation 2003; 76: 120-129.
4. Leventhal JR, Gallon L, Kaufman DB. Alemtuzumab (Campath 1-H) facilitates prednisone-free immunosuppression iin kidney transplant recipients. Am J Transplant 2003; 3: S310.
5. Marcos A, Eghtesad B, Fung JJ et al. Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: With particular reference to hepatitis C virus. Transplantation 2004; 78: 966-971.
6. Reyes J, Mazariegos GV, bu-Elmagd K et al. Intestinal transplantation under tacrolimus monotherapy after perioperative lymphoid depletion with rabbit anti-thymocyte globulin (thymoglobulin). Am J Transplant 2005; 5: 1430-1436.
7. Shapiro R, Basu A, Tan H et al. Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with Thymoglobulin or Campath. J Am Coll Surg 2005; 200: 505-515.
8. McCurry KR, Iacono A, Zeevi A et al. Early outcomes in human lung transplantation with Thymoglobulin or Campath-1H for recipient pretreatment followed by posttransplant tacrolimus nearmonotherapy. J Thorac Cardiovasc Surg 2005; 130: 528-537.
9. Pearl JP, Parris J, Hale DA et al. Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. Am J Transplant 2005; 5: 465-474.
10. Duncan AJ, Dummer JS, Paradis IL et al. Cytomegalovirus infection and survival in lung transplant recipients. J Heart Lung Transplant 1991; 10: 638-644.
11. Ettinger NA, Bailey TC, Trulock EP et al. Cytomegalovirus infection and pneumonitis. Impact after isolated lung transplantation. Washington University Lung Transplant Group. Am Rev Respir Dis 1993; 147: 1017-1023.
12. Zeevi A, Uknis ME, Spichty KJ et al. Proliferation of cytomegalovirus-primed lymphocytes in bronchoalveolar lavages from lung transplant patients. Transplantation 1992; 54: 635-639.
13. Zeevi A, Morel P, Spichty K et al. Clinical significance of CMV-specific T helper responses in lung transplant recipients. Hum Immunol 1998; 59: 768-775.
14. Zeevi A, Spichty K, Banas R et al. Clinical significance of cytomegalovirus-specific T helper responses and cytokine production in lung transplant recipients. Intervirology 1999; 42: 291-300.
15. Kowalski R, Post D, Schneider MC et al. Immune cell function testing: An adjunct to therapeutic drug monitoring in transplant patient management. Clin Transplant 2003; 17: 77-88.
16. Kowalski R, Post DR, Mannon RB et al. Assessing relative risks of infection and rejection: Ameta-analysis using an immune function assay. 82, 2006. Transplantation, in press.
17. Hertz MI, Jordan C, Savik SK et al. Randomized trial of daily versus three-times-weekly prophylactic ganciclovir after lung and heart-lung transplantation. J Heart Lung Transplant 1998; 17: 913-920.
18. Limaye AP. Ganciclovir-resistant cytomegalovirus in organ transplant recipients. Clin Infect Dis 2002; 35: 866-872.
19. Limaye AP, Bakthavatsalam R, Kim HW et al. Impact of cytomegalovirus in organ transplant recipients in the era of antiviral prophylaxis. Transplantation 2006; 81: 1645-1652.
20. Zamora MR, Nicolls MR, Hodges TN et al. Following universal prophylaxis with intravenous ganciclovir and cytomegalovirus immune globulin, valganciclovir is safe and effective for prevention of CMV infection following lung transplantation. Am J Transplant 2004; 4: 1635-1642.
21. Boivin G, Goyette N, Gilbert C, Humar A, Covington E. Clinical impact of ganciclovir-resistant cytomegalovirus infections in solid organ transplant patients. Transpl Infect Dis 2005; 7: 166-170.
22. Burton CM, Kristensen P, Lutzhoft R et al. Cytomegalovirus infection in lung transplant patients: the role of prophylaxis and recipient-donor serotype matching. Scand J Infect Dis 2006; 38: 281-289.
23. Monforte V, Roman A, Gavalda J et al. Preemptive therapy with intravenous ganciclovir for the prevention of cytomegalovirus disease in lung transplant recipients. Transplant Proc 2005; 37: 4039-4042.
24. Ruttmann E, Geltner C, Bucher B et al. Combined CMV prophylaxis improves outcome and reduces the risk for bronchiolitis obliterans syndrome (BOS) after lung transplantation. Transplantation 2006; 81: 1415-1420.
25. Shlobin OA, West EE, Lechtzin N et al. Persistent cytomegalovirus- specific memory responses in the lung allograft and blood following primary infection in lung transplant recipients. J Immunol 2006; 176: 2625-2634.